MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883912/0/en/MangoRx-Reports-Revenue-Growth-of-108-in-Q1-2024-Fueled-by-Amplified-Customer-Acquisition-and-Early-Market-Penetration.html

Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies today announced that it has recently reported noteworthy growth in both revenue and customer acquisition in the first quarter ended March 31, 2024 as compared to the quarter ended March 31, 2023. Specifically, the company reported an impressive 108% increase in sales, growing from $214,000 USD compared to approximately $100,000 USD in the first quarter of 2023. This revenue growth demonstrates a positive trajectory for the company’s financial performance in Q1 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.